These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35292582)

  • 1. Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis.
    Jambulingam P; Subramanian S; Krishnamoorthy K; Supali T; Fischer P; Dubray C; Fayette C; Lemoine JF; Laman M; King C; Samuela J; Hardy M; Weil GJ
    Am J Trop Med Hyg; 2022 May; 106(5_Suppl):18-25. PubMed ID: 35292582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
    Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
    PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
    Dubray CL; Sircar AD; Beau de Rochars VM; Bogus J; Direny AN; Ernest JR; Fayette CR; Goss CW; Hast M; O'Brian K; Pavilus GE; Sabin DF; Wiegand RE; Weil GJ; Lemoine JF
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008298. PubMed ID: 32511226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
    Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
    Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
    Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.
    Krentel A; Basker N; Beau de Rochars M; Bogus J; Dilliott D; Direny AN; Dubray C; Fischer PU; Ga AL; Goss CW; Hardy M; Howard C; Jambulingam P; King CL; Laman M; Lemoine JF; Mallya S; Robinson LJ; Samuela J; Schechtman KB; Steer AC; Supali T; Tavul L; Weil GJ
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009002. PubMed ID: 33657090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
    Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
    Clin Infect Dis; 2021 Sep; 73(6):994-1002. PubMed ID: 33728462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
    Thomsen EK; Sanuku N; Baea M; Satofan S; Maki E; Lombore B; Schmidt MS; Siba PM; Weil GJ; Kazura JW; Fleckenstein LL; King CL
    Clin Infect Dis; 2016 Feb; 62(3):334-341. PubMed ID: 26486704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial.
    Bjerum CM; Ouattara AF; Aboulaye M; Kouadio O; Marius VK; Andersen BJ; Weil GJ; Koudou BG; King CL
    Clin Infect Dis; 2020 Oct; 71(7):e68-e75. PubMed ID: 31641754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial.
    Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008106. PubMed ID: 32176703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018.
    Willis GA; Mayfield HJ; Kearns T; Naseri T; Thomsen R; Gass K; Sheridan S; Graves PM; Lau CL
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008854. PubMed ID: 33253148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis.
    Weil GJ; Fischer PU; Krentel A
    Am J Trop Med Hyg; 2022 May; 106(5_Suppl):13-17. PubMed ID: 35292585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.
    Weil GJ; Bogus J; Christian M; Dubray C; Djuardi Y; Fischer PU; Goss CW; Hardy M; Jambulingam P; King CL; Kuttiat VS; Krishnamoorthy K; Laman M; Lemoine JF; O'Brian KK; Robinson LJ; Samuela J; Schechtman KB; Sircar A; Srividya A; Steer AC; Supali T; Subramanian S;
    PLoS Med; 2019 Jun; 16(6):e1002839. PubMed ID: 31233507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis.
    Opoku NO; Doe F; Dubben B; Fetcho N; Fischer K; Fischer PU; Gordor S; Goss CW; Gyasi ME; Hoerauf A; Hong AR; Kanza E; King CL; Laryea R; Lew D; Seidu MA; Weil GJ
    PLoS Negl Trop Dis; 2023 May; 17(5):e0011365. PubMed ID: 37205721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India.
    Kshirsagar NA; Gogtay NJ; Garg BS; Deshmukh PR; Rajgor DD; Kadam VS; Thakur PA; Gupta A; Ingole NS; Lazdins-Helds JK
    Parasitol Res; 2017 Oct; 116(10):2683-2694. PubMed ID: 28785847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study.
    Khaemba C; Barry A; Omondi WP; Kirui E; Oluka M; Parthasarathi G; Njenga SM; Guantai A; Aklillu E
    Drug Saf; 2023 Oct; 46(10):961-974. PubMed ID: 37552438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d'Ivoire: A randomized controlled superiority study.
    Bjerum CM; Koudou BG; Ouattara AF; Lew D; Goss CW; Gabo PT; King CL; Fischer PU; Weil GJ; Budge PJ
    PLoS Negl Trop Dis; 2023 Sep; 17(9):e0011633. PubMed ID: 37721964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of albendazole for lymphatic filariasis.
    Horton J
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S33-40. PubMed ID: 19843396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.